ArriVent BioPharma Income Statement (2023-2026) | AVBP

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter) 10.24M20.36M14.28M20.01M16.98M21.78M20.09M20.16M61.29M27.72M32.17M32.17M37.62M
Selling, General & Administrative (Quarter) 1.94M2.23M2.44M3.11M3.70M3.92M4.14M3.54M5.48M5.90M6.15M6.65M8.49M
Restructuring Costs (Quarter) 1.68M1.94M2.08M1.46M2.15M2.44M1.92M2.26M2.31M
Other Operating Expenses (Quarter) -1.68M-1.94M-2.08M-1.46M-2.15M-2.44M-1.92M-2.26M-2.31M
Operating Expenses (Quarter) 12.17M22.58M16.72M23.12M20.67M25.70M24.23M23.70M66.77M33.62M38.32M38.82M46.11M
Operating Income (Quarter) -12.17M-22.58M-16.72M-23.12M-20.67M-25.70M-24.23M-23.70M-66.77M-33.62M-38.32M-38.82M-46.11M
EBIT (Quarter) -12.17M-22.58M-16.72M-23.12M-20.67M-25.70M-24.23M-23.70M-66.77M-33.62M-38.32M-38.82M-46.11M
Non-operating items
Interest & Investment Income (Quarter) 1.02M2.31M1.93M3.26M3.82M3.67M3.07M2.38M2.22M3.34M3.28M2.79M
Net income details
EBT (Quarter) -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M
Profit After Tax (Quarter) -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M
Income from Continuing Operations (Quarter) -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M
Consolidated Net Income (Quarter) -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M
Income towards Parent Company (Quarter) -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M
Net Income towards Common Stockholders (Quarter) -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M
Additional items
EPS (Basic) (Quarter) -9.45-10.79-5.52-7.69-0.70-0.65-0.61-0.61-1.90-0.90-0.83-0.78-0.96
EPS (Weighted Average and Diluted) (Quarter) -9.45-10.79-5.52-7.69-0.70-0.65-0.61-0.61-1.90-0.90-0.83-0.78-0.96
Shares Outstanding (Weighted Average) (Quarter) 1.29M1.64M2.61M2.14M25.05M33.50M30.72M31.47M33.90M34.46M36.97M38.46M45.07M
Shares Outstanding (Diluted Average) (Quarter) 1.29M2.00M2.61M2.14M25.05M29.27M33.58M31.47M33.90M34.46M36.97M38.46M45.07M
EBITDA (Quarter) -12.17M-22.58M-16.72M-23.12M-17.42M-21.87M-20.56M-20.84M-64.19M-31.40M-34.75M-35.74M-43.60M
Shares Outstanding (Quarter) 2.61M2.60M2.67M2.75M33.49M33.51M33.69M33.71M34.04M37.49M40.85M42.45M45.31M